Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C P Cross

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Cancer Research|April 5, 2005
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Andreas Reiter, Christoph Walz, Ann Watmore, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
Nature Genetics|April 30, 2014
Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancerLars A Forsberg, Chiara Rasi, Niklas Malmqvist, et al.
The New England Journal of Medicine|April 15, 2005
DNA topoisomerase II in therapy-related acute promyelocytic leukemiaAnita R Mistry, Carolyn A Felix, Ryan J Whitmarsh, et al.
Frontiers in Oncology|July 15, 2022
<i>TP53</i> Mutations Identified Using NGS Comprise the Overwhelming Majority of <i>TP53</i> Disruptions in CLL: Results From a Multicentre StudyMark A Catherwood, Dorte Wren, Laura Chiecchio, et al.
Blood|September 30, 2025
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40William J Tapper, Ahmed A Z Dawoud, Joannah Score, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Prognostic score including gene mutations in chronic myelomonocytic leukemiaRaphaël Itzykson, Olivier Kosmider, Aline Renneville, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Cancer Research|April 5, 2005
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Andreas Reiter, Christoph Walz, Ann Watmore, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
Nature Genetics|April 30, 2014
Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancerLars A Forsberg, Chiara Rasi, Niklas Malmqvist, et al.
The New England Journal of Medicine|April 15, 2005
DNA topoisomerase II in therapy-related acute promyelocytic leukemiaAnita R Mistry, Carolyn A Felix, Ryan J Whitmarsh, et al.
Frontiers in Oncology|July 15, 2022
<i>TP53</i> Mutations Identified Using NGS Comprise the Overwhelming Majority of <i>TP53</i> Disruptions in CLL: Results From a Multicentre StudyMark A Catherwood, Dorte Wren, Laura Chiecchio, et al.
Blood|September 30, 2025
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40William J Tapper, Ahmed A Z Dawoud, Joannah Score, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Prognostic score including gene mutations in chronic myelomonocytic leukemiaRaphaël Itzykson, Olivier Kosmider, Aline Renneville, et al.
Pageof 23